Sapporo Medical University – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 34
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: S180EA2E272EN
Leaflet:

Download PDF Leaflet

Sapporo Medical University – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Sapporo Medical University – Developmental Therapeutics Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Sapporo Medical University – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Sapporo Medical University human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Sapporo Medical University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Sapporo Medical University’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Sapporo Medical University’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Sapporo Medical University in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Sapporo Medical University’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Sapporo Medical University.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Sapporo Medical University and identify potential opportunities in those areas.
Sapporo Medical University Snapshot
Key Information
Key Facts
Sapporo Medical University – Research and Development Overview
Key Therapeutic Areas
Sapporo Medical University – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Sapporo Medical University – Pipeline Products Glance
Sapporo Medical University Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sapporo Medical University – Drug Profiles
CPT-11
  Product Description
  Mechanism of Action
  R&D Progress
CPT-11 + CDDP
  Product Description
  Mechanism of Action
  R&D Progress
Docetaxel + Cisplatin + TS-1
  Product Description
  Mechanism of Action
  R&D Progress
TS-1 + Gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
AYRPVSRNI + IFA
  Product Description
  Mechanism of Action
  R&D Progress
AYRPVSRNI + IFA + Interferon Alpha
  Product Description
  Mechanism of Action
  R&D Progress
Survivin-2B Peptide + IFA
  Product Description
  Mechanism of Action
  R&D Progress
Survivin-2B Peptide + IFA + GM-CSF
  Product Description
  Mechanism of Action
  R&D Progress
Survivin-2B Peptide + IFA + IFN-Alpha
  Product Description
  Mechanism of Action
  R&D Progress
Survivin-2B Peptide + IFA + IL-2
  Product Description
  Mechanism of Action
  R&D Progress
Survivin-2B peptide vaccination
  Product Description
  Mechanism of Action
  R&D Progress
Sapporo Medical University – Pipeline Analysis
Sapporo Medical University – Pipeline Products by Therapeutic Class
Sapporo Medical University Pipeline Products By Target
Sapporo Medical University – Pipeline Products by Route of Administration
Sapporo Medical University – Pipeline Products by Molecule Type
Sapporo Medical University – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Sapporo Medical University Detailed Deal Summary
Acquisition
OHL ZS acquires Tratova Strojni Spolecnost from Ceske Drahy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 34

LIST OF TABLES

Sapporo Medical University – Pipeline by Therapy Area and Indication, 2010
Sapporo Medical University – Pipeline by Stage of Development, 2010
Sapporo Medical University – Monotherapy Products in Pipeline, 2010
Sapporo Medical University – Combination Treatment Modalities in Pipeline, 2010
Sapporo Medical University - Phase II, 2010
Sapporo Medical University - Phase I, 2010
Sapporo Medical University - Pipeline By Therapeutic Class, 2010
Sapporo Medical University - Pipeline By Target, 2010
Sapporo Medical University – Pipeline By Route of Administration, 2010
Sapporo Medical University – Pipeline By Molecule Type, 2010 30

LIST OF FIGURES

Sapporo Medical University – Pipeline by Therapy Area and Indication, 2010
Sapporo Medical University – Pipeline by Stage of Development, 2010
Sapporo Medical University – Monotherapy Products in Pipeline, 2010
Sapporo Medical University – Combination Treatment Modalities in Pipeline, 2010
Sapporo Medical University – Pipeline By Therapeutic Class, 2010
Sapporo Medical University - Pipeline By Target, 2010
Sapporo Medical University – Pipeline By Route of Administration, 2010
Sapporo Medical University – Pipeline By Molecule Type, 2010 30

Ask Your Question

Sapporo Medical University – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: